Diadema Partners »

Eliem Therapeutics shares owned by Diadema Partners

Quarter-by-quarter ownership of Eliem Therapeutics (CLYM) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Eliem Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Eliem Therapeutics held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Eliem Therapeutics by Diadema Partners

Quarter filed Position value Share count Share price at filing
2025-09-30 $274k 137k 2.01

More positions owned by Diadema Partners

Jazz Pharmaceuticals Shs Usd (JAZZ)
Soleno Therapeutics (SLNO)
Uniqure Nv SHS Put Option (QURE)
Regeneron Pharmaceuticals (REGN)
Viking Therapeutics (VKTX)
Bristol Myers Squibb (BMY)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
BioMarin Pharmaceutical (BMRN)
Avidity Biosciences Ord (RNA)
Agios Pharmaceuticals Call Option (AGIO)
Ultragenyx Pharmaceutical (RARE)
Incyte Corporation Call Option (INCY)
Intellia Therapeutics Call Option (NTLA)
Vaxcyte (PCVX)
Eli Lilly & Co. Put Option (LLY)

View all positions for Diadema Partners

Top funds holding Eliem Therapeutics

RA Capital Management
Vanguard Group
Affinity Asset Advisors
Kynam Capital Management
Tang Capital Management
BlackRock
Peapod Lane Capital
Cantor Fitzgerald, L. P.
Renaissance Technologies
Deep Track Capital
Alyeska Investment Group
Millennium Management
Nan Fung Trinity
Sphera Funds Management
UBS Group

View all funds holding Eliem Therapeutics